Ensysce Biosciences Gets $14 Million Federal Grant for Continued Development of Potential Opioid With Overdose Protection -- Shares Soar Pre-Bell

MT Newswires Live08-27

Ensysce Biosciences (ENSC) said Tuesday that it has received a $14 million grant from the National Institutes of Health and National Institute on Drug Abuse to continue developing PF614-MPAR, an abuse-deterrent opioid with overdose protection.

PF614-MPAR received breakthrough therapy designation from the US Food and Drug Administration in January, the company said.

Ensysce said funding from the award will be available for three years, allowing for the completion of a phase 1b clinical trial aimed at expanding the product offering identified in a study conducted to verify the overdose protection of the Multi-Pill Abuse Resistance platform.

The funding adds to the two previous grants totaling more than $26 million for the initial work on the MPAR and opioid use disorder programs, the company said.

Shares of Ensysce Biosciences were up 60% in recent premarket activity on Tuesday.

Price: 0.6999, Change: +0.27, Percent Change: +62.01

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2462416019?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-27 21:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2462416019","market":"us","top_or_hot":-1,"title":"Ensysce Biosciences Gets $14 Million Federal Grant for Continued Development of Potential Opioid With Overdose Protection -- Shares Soar Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Ensysce Biosciences (ENSC) said Tuesday that it has received a $14 million grant from the National Institutes of Health and National Institute on Drug Abuse to continue developing PF614-MPAR, an abuse-deterrent opioid with overdose protection.</p><p>PF614-MPAR received breakthrough therapy designation from the US Food and Drug Administration in January, the company said.</p><p>Ensysce said funding from the award will be available for three years, allowing for the completion of a phase 1b clinical trial aimed at expanding the product offering identified in a study conducted to verify the overdose protection of the Multi-Pill Abuse Resistance platform.</p><p>The funding adds to the two previous grants totaling more than $26 million for the initial work on the MPAR and opioid use disorder programs, the company said.</p><p>Shares of Ensysce Biosciences were up 60% in recent premarket activity on Tuesday.</p><p>Price: 0.6999, Change: +0.27, Percent Change: +62.01</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ensysce Biosciences Gets $14 Million Federal Grant for Continued Development of Potential Opioid With Overdose Protection -- Shares Soar Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnsysce Biosciences Gets $14 Million Federal Grant for Continued Development of Potential Opioid With Overdose Protection -- Shares Soar Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-27 21:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ensysce Biosciences (ENSC) said Tuesday that it has received a $14 million grant from the National Institutes of Health and National Institute on Drug Abuse to continue developing PF614-MPAR, an abuse...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2462416019","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2462416019","pubTimestamp":1724764085,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Ensysce Biosciences  said Tuesday that it has received a $14 million grant from the National Institutes of Health and National Institute on Drug Abuse to continue developing PF614-MPAR, an abuse-deterrent opioid with overdose protection.PF614-MPAR received breakthrough therapy designation from the US Food and Drug Administration in January, the company said.Ensysce said funding from the award will be available for three years, allowing for the completion of a phase 1b clinical trial aimed at expanding the product offering identified in a study conducted to verify the overdose protection of the Multi-Pill Abuse Resistance platform.The funding adds to the two previous grants totaling more than $26 million for the initial work on the MPAR and opioid use disorder programs, the company said.Shares of Ensysce Biosciences were up 60% in recent premarket activity on Tuesday.Price: 0.6999, Change: +0.27, Percent Change: +62.01","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ENSC":"Ensysce Biosciences Inc."},"translate_title":"Ensysce Biosciences获得1400万美元联邦拨款，用于继续开发具有过量保护作用的潜在阿片类药物——盘前股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"US10Y.BOND":1,"US12M.BOND":1,"US2Y.BOND":1,"US30Y.BOND":1,"US3Y.BOND":1,"US5Y.BOND":1,"US6M.BOND":1,"US7Y.BOND":1,"ENSC":0.9,"US912797GL51.BOND":0.6,"US912797GW17.BOND":0.6,"US912797HE00.BOND":0.6},"content_text":"Ensysce Biosciences (ENSC) said Tuesday that it has received a $14 million grant from the National Institutes of Health and National Institute on Drug Abuse to continue developing PF614-MPAR, an abuse-deterrent opioid with overdose protection.PF614-MPAR received breakthrough therapy designation from the US Food and Drug Administration in January, the company said.Ensysce said funding from the award will be available for three years, allowing for the completion of a phase 1b clinical trial aimed at expanding the product offering identified in a study conducted to verify the overdose protection of the Multi-Pill Abuse Resistance platform.The funding adds to the two previous grants totaling more than $26 million for the initial work on the MPAR and opioid use disorder programs, the company said.Shares of Ensysce Biosciences were up 60% in recent premarket activity on Tuesday.Price: 0.6999, Change: +0.27, Percent Change: +62.01","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2462416019"}